vs
Side-by-side financial comparison of CARRIAGE SERVICES INC (CSV) and Travere Therapeutics, Inc. (TVTX). Click either name above to swap in a different company.
Travere Therapeutics, Inc. is the larger business by last-quarter revenue ($129.7M vs $105.5M, roughly 1.2× CARRIAGE SERVICES INC). On growth, Travere Therapeutics, Inc. posted the faster year-over-year revenue change (73.4% vs 8.0%). Over the past eight quarters, Travere Therapeutics, Inc.'s revenue compounded faster (77.0% CAGR vs 1.0%).
Jardine Cycle & Carriage Limited is the investment holding company of Jardines in Southeast Asia. It is currently 75% held by the conglomerate.
Travere Therapeutics, Inc. is a global biopharmaceutical firm developing and commercializing innovative therapies for patients with rare, serious, life-threatening diseases. Its key segments cover rare nephrology, hepatology and metabolic disorders, serving markets across North America, Europe and other global regions.
CSV vs TVTX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $105.5M | $129.7M |
| Net Profit | $12.3M | — |
| Gross Margin | 34.8% | 98.0% |
| Operating Margin | 23.3% | -25.0% |
| Net Margin | 11.6% | — |
| Revenue YoY | 8.0% | 73.4% |
| Net Profit YoY | 24.5% | — |
| EPS (diluted) | $0.76 | $0.04 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $105.5M | $129.7M | ||
| Q3 25 | $102.7M | $164.9M | ||
| Q2 25 | $102.1M | $114.4M | ||
| Q1 25 | $107.1M | $81.7M | ||
| Q4 24 | $97.7M | $74.8M | ||
| Q3 24 | $100.7M | $62.9M | ||
| Q2 24 | $102.3M | $54.1M | ||
| Q1 24 | $103.5M | $41.4M |
| Q4 25 | $12.3M | — | ||
| Q3 25 | $6.6M | $25.7M | ||
| Q2 25 | $11.7M | $-12.8M | ||
| Q1 25 | $20.9M | $-41.2M | ||
| Q4 24 | $9.9M | — | ||
| Q3 24 | $9.9M | $-54.8M | ||
| Q2 24 | $6.3M | $-70.4M | ||
| Q1 24 | $7.0M | $-136.1M |
| Q4 25 | 34.8% | 98.0% | ||
| Q3 25 | 35.3% | 99.0% | ||
| Q2 25 | 35.2% | 98.7% | ||
| Q1 25 | 35.3% | 94.3% | ||
| Q4 24 | 34.4% | 96.6% | ||
| Q3 24 | 35.2% | 97.4% | ||
| Q2 24 | 36.2% | 96.2% | ||
| Q1 24 | 36.0% | 96.4% |
| Q4 25 | 23.3% | -25.0% | ||
| Q3 25 | 17.0% | 15.1% | ||
| Q2 25 | 23.5% | -11.1% | ||
| Q1 25 | 29.5% | -52.2% | ||
| Q4 24 | 21.6% | -81.2% | ||
| Q3 24 | 22.7% | -89.3% | ||
| Q2 24 | 18.0% | -125.1% | ||
| Q1 24 | 18.8% | -336.5% |
| Q4 25 | 11.6% | — | ||
| Q3 25 | 6.4% | 15.6% | ||
| Q2 25 | 11.5% | -11.1% | ||
| Q1 25 | 19.5% | -50.4% | ||
| Q4 24 | 10.1% | — | ||
| Q3 24 | 9.8% | -87.1% | ||
| Q2 24 | 6.1% | -130.1% | ||
| Q1 24 | 6.7% | -328.9% |
| Q4 25 | $0.76 | $0.04 | ||
| Q3 25 | $0.41 | $0.28 | ||
| Q2 25 | $0.74 | $-0.14 | ||
| Q1 25 | $1.34 | $-0.47 | ||
| Q4 24 | $0.62 | $-0.71 | ||
| Q3 24 | $0.63 | $-0.70 | ||
| Q2 24 | $0.40 | $-0.91 | ||
| Q1 24 | $0.45 | $-1.76 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.7M | $93.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $254.8M | $114.8M |
| Total Assets | $1.3B | $605.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $1.7M | $93.0M | ||
| Q3 25 | $1.2M | $110.9M | ||
| Q2 25 | $1.4M | $75.2M | ||
| Q1 25 | $4.6M | $61.9M | ||
| Q4 24 | $1.2M | $58.5M | ||
| Q3 24 | $1.3M | $36.4M | ||
| Q2 24 | $1.5M | $32.3M | ||
| Q1 24 | $1.7M | $43.3M |
| Q4 25 | $254.8M | $114.8M | ||
| Q3 25 | $242.1M | $73.6M | ||
| Q2 25 | $235.4M | $32.7M | ||
| Q1 25 | $223.1M | $32.8M | ||
| Q4 24 | $208.6M | $59.1M | ||
| Q3 24 | $198.1M | $-30.5M | ||
| Q2 24 | $187.9M | $15.1M | ||
| Q1 24 | $179.6M | $74.1M |
| Q4 25 | $1.3B | $605.2M | ||
| Q3 25 | $1.3B | $538.6M | ||
| Q2 25 | $1.3B | $555.3M | ||
| Q1 25 | $1.3B | $548.8M | ||
| Q4 24 | $1.3B | $594.1M | ||
| Q3 24 | $1.3B | $504.4M | ||
| Q2 24 | $1.3B | $551.1M | ||
| Q1 24 | $1.3B | $663.5M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $14.1M | $60.7M |
| Free Cash FlowOCF − Capex | $6.2M | — |
| FCF MarginFCF / Revenue | 5.9% | — |
| Capex IntensityCapex / Revenue | 7.5% | — |
| Cash ConversionOCF / Net Profit | 1.15× | — |
| TTM Free Cash FlowTrailing 4 quarters | $40.1M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $14.1M | $60.7M | ||
| Q3 25 | $24.7M | $14.3M | ||
| Q2 25 | $8.1M | $5.0M | ||
| Q1 25 | $13.8M | $-42.2M | ||
| Q4 24 | $9.3M | $-35.7M | ||
| Q3 24 | $20.9M | $-42.5M | ||
| Q2 24 | $2.2M | $-40.2M | ||
| Q1 24 | $19.7M | $-119.0M |
| Q4 25 | $6.2M | — | ||
| Q3 25 | $18.0M | $14.2M | ||
| Q2 25 | $5.2M | — | ||
| Q1 25 | $10.6M | — | ||
| Q4 24 | $4.9M | — | ||
| Q3 24 | $16.2M | — | ||
| Q2 24 | $-1.4M | $-40.3M | ||
| Q1 24 | $16.2M | — |
| Q4 25 | 5.9% | — | ||
| Q3 25 | 17.5% | 8.6% | ||
| Q2 25 | 5.1% | — | ||
| Q1 25 | 9.9% | — | ||
| Q4 24 | 5.0% | — | ||
| Q3 24 | 16.1% | — | ||
| Q2 24 | -1.4% | -74.5% | ||
| Q1 24 | 15.6% | — |
| Q4 25 | 7.5% | — | ||
| Q3 25 | 6.5% | 0.1% | ||
| Q2 25 | 2.8% | — | ||
| Q1 25 | 3.0% | — | ||
| Q4 24 | 4.5% | — | ||
| Q3 24 | 4.6% | 0.0% | ||
| Q2 24 | 3.5% | 0.2% | ||
| Q1 24 | 3.4% | 0.0% |
| Q4 25 | 1.15× | — | ||
| Q3 25 | 3.76× | 0.56× | ||
| Q2 25 | 0.69× | — | ||
| Q1 25 | 0.66× | — | ||
| Q4 24 | 0.94× | — | ||
| Q3 24 | 2.11× | — | ||
| Q2 24 | 0.34× | — | ||
| Q1 24 | 2.83× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CSV
| Propertyand Merchandise | $47.8M | 45% |
| Cemetery Interment Rights | $24.8M | 23% |
| Merchandise | $18.9M | 18% |
| Other Revenue | $10.2M | 10% |
| Other | $3.9M | 4% |
TVTX
| FILSPARI | $103.3M | 80% |
| Tiopronin Products | $23.3M | 18% |
| License | $3.1M | 2% |
